ReviewClinical reviews in allergy & immunology2009
Factor VIII inhibitors: risk factors and methods for prevention and immune modulation.
Review in Clinical reviews in allergy & immunology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 31 citations in OpenAlex.
- CD4Cellular immunology · 2020Article
- Characterization of a genetically engineered mouse model of hemophilia A with complete deletion of the F8 gene.Journal of thrombosis and haemostasis : JTH · 2016Article
- Polymeric synthetic nanoparticles for the induction of antigen-specific immunological tolerance.Proceedings of the National Academy of Sciences of the United States of America · 2015Article
- Genetics of transfusion recipient alloimmunization: can clues from susceptibility to autoimmunity pave the way?Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie · 2014Review
- De novo mutation in DMD gene in a patient with combined hemophilia A and Duchenne muscular dystrophy.International journal of hematology · 2014Article
- Detection of intracellular Factor VIII protein in peripheral blood mononuclear cells by flow cytometry.BioMed research international · 2013Article
- Polymorphisms in the F8 gene and MHC-II variants as risk factors for the development of inhibitory anti-factor VIII antibodies during the treatment of hemophilia a: a computational assessment.PLoS computational biology · 2013Article
- Gene therapy for haemophilia: prospects and challenges to prevent or reverse inhibitor formation.British journal of haematology · 2012Review
- Pharmacogenetics and the immunogenicity of protein therapeutics.Nature biotechnology · 2011Article
- Haemophilia management: time to get personal?Haemophilia : the official journal of the World Federation of Hemophilia · 2011Review
- Tilt balance towards regulation: evolving new strategy for treatment of hemophilia inhibitors.Journal of thrombosis and haemostasis : JTH · 2011Article
- In vivo expansion of regulatory T cells with IL-2/IL-2 mAb complexes prevents anti-factor VIII immune responses in hemophilia A mice treated with factor VIII plasmid-mediated gene therapy.Molecular therapy : the journal of the American Society of Gene Therapy · 2011Article
- Delineating the Hemostaseome as an aid to individualize the analysis of the hereditary basis of thrombotic and bleeding disorders.Human genetics · 2011Review
- A role for thrombin in the initiation of the immune response to therapeutic factor VIII.Blood · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patients with hemophilia A are deficient in coagulation Factor VIII. This bleeding disorder can be treated with Factor VIII replacement therapy, but close to a third of patients will be immunized to the treatment and begin to form inhibitory antibodies known as "inhibitors". These inhibitors will render the treatment ineffective and represent the most severe complication in the treatment of hemophilia A. In this review, we highlight factors involved in inhibitor development and emphasize research being done to modulate the immune response to this life-saving therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.